ArticleJournal of experimental & clinical cancer research : CR2022

RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.

Qiu Tu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.